Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
about
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancerMuscle-invasive urothelial bladder cancer: an update on systemic therapyOptimal management of muscle-invasive bladder cancer - a reviewPerioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial CarcinomaAdjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgeryHow individual participant data meta-analyses have influenced trial design, conduct, and analysisSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.[Adjuvant chemotherapy for invasive bladder cancer (individual patient data)].Systemic therapy in bladder canceruPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practiceUrothelial carcinoma management in elderly or unfit patients.The Role of Population-Based Observational Research in Bladder CancerBenefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy.Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.The Rationale for Post-Operative Radiation in Localized Bladder Cancer.New advances in genitourinary cancer: evidence gathered in 2014.Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.Bladder cancer in 2015: Improving indication, technique and outcome of radical cystectomy.Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.Emerging drugs for urothelial (bladder) cancer.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Chemotherapy for Muscle-Invasive Bladder Cancer.Improving Systemic Chemotherapy for Bladder Cancer.A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study.Current Concepts in the Management of Muscle Invasive Bladder Cancer.Landmarks in the treatment of muscle-invasive bladder cancer.Nivolumab for the treatment of bladder cancer.Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient.Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy.Independent prognostic miRNAs for bladder urothelial carcinoma.Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.
P2860
Q26773664-559F343E-F333-4E43-9945-D0CF4E4C574DQ26775780-C0ED9B1E-D683-4312-A781-5201E11C9B32Q26784038-2B76B8B2-B003-4FBE-9369-6B7D9D994001Q27024948-64346B14-97E1-4295-A44A-665ACAF50AA4Q28066214-A017D9EA-5EC0-4AF4-9CD1-84B29DDC7719Q28074930-418AB810-B13F-4514-B604-6207802DDBD5Q28607751-BA800294-D3A4-45D1-96F7-7108B9307B5DQ30240816-37C2D3D3-F137-4E60-80BF-55B9152E4CE6Q30249047-7E356569-A913-4A20-A5F0-1E8A90BADAE3Q31154300-7EC5076F-36DC-42A2-9BD3-7454A6B74FDBQ33578564-0A227CF8-1286-45FF-8C06-C32E970FDADFQ35751445-A9C2836A-E222-436C-841A-C9AB6C8BE176Q36338035-C1692F53-8459-4131-B963-228A66AD00FEQ36631963-FCD46F03-D822-4E83-AB7F-38DC077BDA76Q37030514-BA543E63-BE37-4C77-812F-7C676A81F61FQ37053750-0A83A109-2EBB-4757-B7DE-CB399A30E6B0Q37053991-1D945ABB-07C1-473E-8EC7-D78B685B2A6AQ37234834-1E58282C-3F98-4E16-B657-B37A6293BA40Q37475193-FC843BC3-4F1C-4211-AB4E-D220EFCDA31EQ37530339-6166E8CE-B8C2-423D-9B14-5D9DDC031ADAQ37610539-7D422B78-A9B2-4AE5-91C5-2283EB705A88Q38557894-7479E443-BFB2-4322-913F-6AE7CFBDF0FBQ38615547-749754F0-61B8-40C4-AB6D-7B8C8F6D379BQ38644602-C4C2A797-FDA4-4717-9E1F-15D7ECBC24C7Q38654974-90616879-E935-4462-A0E3-DE586A212B56Q38677414-031CB8F5-47CD-4CA5-B2F5-00B9458B2344Q38701535-BBBF50D9-0799-493C-83B0-5FD7BC627763Q38711504-C3EEEE7B-E4D5-4896-BE14-CD5F2C4EEA4EQ38777610-9CE28FB4-D3F0-4EDA-B9D9-D3B23CAC6C17Q38817683-E750F72F-E3B9-4FCF-A36A-33574AFC9961Q38852690-83D65D57-C734-4A3E-9175-2D81BD01B273Q38941344-A1E189E5-25EE-4ADB-B7C4-C45F1C2F8753Q39105784-FC0E3BA3-9796-41EE-A37B-47E7A20A43A2Q39413207-16F70533-D41F-4993-985E-4E399C45B8EAQ39454030-E329D053-0B32-49C9-993A-43840F11A074Q39855461-C523DFD2-B7ED-497F-816A-F4459B93C058Q41233576-E042208B-B19D-4B18-A7EF-95489E5DECFFQ41273398-4DA0C84D-A848-40EA-88D5-5B86FBEFEEB7Q41612405-E277C2D2-4399-41C5-9A58-A26B70BA0397Q41790109-DBC4BF74-9334-4D74-82E8-5F9665EA147D
P2860
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@ast
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@en
type
label
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@ast
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@en
prefLabel
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@ast
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@en
P2093
P50
P1433
P1476
Immediate versus deferred chem ...... bel, randomised phase 3 trial.
@en
P2093
Antony Verbaeys
Christine Théodore
Cora N Sternberg
Danielle Charpentier
European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group
Frédéric Rolland
George Thalmann
German Association of Urologic Oncology
Groupe d'Etude des Tumeurs Urogénitales
Herlinde Dumez
P356
10.1016/S1470-2045(14)71160-X
P50
P577
2014-12-11T00:00:00Z